SCHEMBL22532691

SCHEMBL22532691

Fc1ccc(N2CCC(Cc3ccc(CCl)cc3)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.52
▸ MAPT P10636 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ STAT3 P40763 1/20 0.47
▸ RPS6KB1 P23443 1/20 0.46
▸ GMNN O75496 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ THPO P40225 1/20 0.46
▸ MTOR P42345 1/20 0.46
▸ BLM P54132 1/20 0.46
▸ GRIN1 Q05586 1/20 0.46
▸ GRIN2B Q13224 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22532645 0.85 KDM4E (0.53) HRH3MAPTKDM4EALDH1A1STAT3
SCHEMBL7824827 0.84 SLC6A2 (0.58) HRH3MAPTKDM4EALDH1A1TSHR
SCHEMBL22532727 0.83 CCR3 (0.61) ALDH1A1GMNNTP53CYP3A4ALOX15
SCHEMBL14439429 0.77 GRIN2B (0.52) STAT3RPS6KB1GMNNTP53CYP3A4
SCHEMBL5988539 0.76 MAPT (0.77) MAPTKDM4E
SCHEMBL13279296 0.76 GRIN2B (0.50) GRIN1GRIN2B
SCHEMBL5888881 0.75 ALDH1A1 (0.65) MAPTKDM4EALDH1A1TP53ALOX15
SCHEMBL22532700 0.74 CETP (0.49) MAPTKDM4EALDH1A1TSHR
SCHEMBL3634313 0.74 EPHX2 (0.48) STAT3GMNNTP53CYP3A4ALOX15
SCHEMBL3303532 0.74 HRH3 (0.52) HRH3MAPTKDM4EALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 THERAPEUTICS, INC. (US) 2023-03-16 — — US disclosed
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos C4 THERAPEUTICS, INC. (US) 2022-08-09 — — US disclosed
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos C4 THERAPEUTICS, INC. (US) 2022-08-09 — — US disclosed
EP-3953332-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 Therapeutics, Inc. (US) 2022-02-16 — — EP disclosed
WO-2020210630-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 THERAPEUTICS, INC. (US) 2020-10-15 — — WO disclosed
WO-2020210630-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 THERAPEUTICS, INC. (US) 2020-10-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos CRBN, IKZF1, IKZF3 HRH3 4201/4885MAPT 1742/4885KDM4E 315/4885
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS CRBN, IKZF1, IKZF3 HRH3 4201/4885MAPT 1742/4885KDM4E 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback